Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$5.63 - $8.27 $1.8 Million - $2.65 Million
320,552 Added 31.94%
1,324,246 $8.97 Million
Q3 2023

Nov 14, 2023

BUY
$6.71 - $11.83 $6.73 Million - $11.9 Million
1,003,694 New
1,003,694 $6.73 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $266M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Pictet Asset Management Holding Sa Portfolio

Follow Pictet Asset Management Holding Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pictet Asset Management Holding Sa, based on Form 13F filings with the SEC.

News

Stay updated on Pictet Asset Management Holding Sa with notifications on news.